Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 8/20 | 0.47 |
| ▸ | JAK1 | P23458 | 6/20 | 0.46 |
| ▸ | JAK2 | O60674 | 4/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | CHUK | O15111 | 2/20 | 0.35 |
| ▸ | NEK2 | P51955 | 1/20 | 0.35 |
| ▸ | SGK1 | O00141 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | CIT | O14578 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | PDE1A | P54750 | 1/20 | 0.34 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30008726 | 0.83 | JAK1 (0.47) | KITJAK1JAK2TYK2JAK3 | |
| SCHEMBL30009301 | 0.83 | JAK1 (0.59) | KITJAK1JAK2TYK2JAK3 | |
| SCHEMBL30009864 | 0.82 | KIT (0.54) | KITJAK1JAK2TYK2JAK3 | |
| SCHEMBL30356129 | 0.76 | JAK1 (0.75) | JAK1 | |
| SCHEMBL20917996 | 0.76 | JAK1 (0.75) | JAK1 | |
| SCHEMBL3928174 | 0.73 | AKT2 (0.43) | CHUKNEK2 | |
| SCHEMBL30009155 | 0.70 | IKBKB (0.63) | JAK1CHUKIKBKBCIT | |
| SCHEMBL30008756 | 0.69 | IKBKB (0.56) | KITJAK1JAK2TYK2JAK3 | |
| SCHEMBL30009793 | 0.69 | KIT (0.71) | KITJAK1JAK2TYK2JAK3 | |
| SCHEMBL30009502 | 0.69 | KIT (0.64) | KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | claimed |
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | KIT 3668/4885JAK1 83/4885JAK2 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.